- Home
- DSY vs TLSI Comparison
DSY vs TLSI Comparison
Compare DSY & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSY
- TLSI
- Stock Information
- Founded
- DSY 2020
- TLSI 2010
- Country
- DSY China
- TLSI United States
- Employees
- DSY N/A
- TLSI N/A
- Industry
- DSY
- TLSI Medical Specialities
- Sector
- DSY
- TLSI Health Care
- Exchange
- DSY Nasdaq
- TLSI Nasdaq
- Market Cap
- DSY 130.7M
- TLSI 150.3M
- IPO Year
- DSY N/A
- TLSI N/A
- Fundamental
- Price
- DSY $2.60
- TLSI $4.99
- Analyst Decision
- DSY
- TLSI Strong Buy
- Analyst Count
- DSY 0
- TLSI 6
- Target Price
- DSY N/A
- TLSI $11.75
- AVG Volume (30 Days)
- DSY 51.6K
- TLSI 32.6K
- Earning Date
- DSY 02-10-2025
- TLSI 11-14-2024
- Dividend Yield
- DSY N/A
- TLSI N/A
- EPS Growth
- DSY 120.37
- TLSI N/A
- EPS
- DSY 0.01
- TLSI N/A
- Revenue
- DSY $7,323,356.00
- TLSI $26,891,000.00
- Revenue This Year
- DSY N/A
- TLSI $60.90
- Revenue Next Year
- DSY N/A
- TLSI $53.73
- P/E Ratio
- DSY $279.76
- TLSI N/A
- Revenue Growth
- DSY 16.37
- TLSI 67.90
- 52 Week Low
- DSY $0.75
- TLSI $3.50
- 52 Week High
- DSY $13.47
- TLSI $10.42
- Technical
- Relative Strength Index (RSI)
- DSY 43.40
- TLSI 59.99
- Support Level
- DSY $2.65
- TLSI $4.53
- Resistance Level
- DSY $3.64
- TLSI $4.92
- Average True Range (ATR)
- DSY 0.43
- TLSI 0.27
- MACD
- DSY -0.04
- TLSI -0.01
- Stochastic Oscillator
- DSY 14.80
- TLSI 78.48
About DSY Big Tree Cloud Holdings Limited Ordinary Shares
Big Tree Cloud Holdings Ltd is a consumer-oriented, mission-driven, and technology-empowered company engaged in the development, production, and sales of personal care products and other consumer goods. In particular, it is focused on the development and production of feminine pads and other feminine hygiene products. Through its platform, the company focuses on high-quality product development, deep customer engagement, and efficient sales and marketing.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.